vs
CNB FINANCIAL CORP（CCNE）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
CNB FINANCIAL CORP的季度营收约是RIGEL PHARMACEUTICALS INC的1.2倍（$86.4M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 24.0%，领先360.1%），CNB FINANCIAL CORP同比增速更快（45.5% vs 21.2%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 26.3%）
CNB金融集团（宾夕法尼亚州）是美国区域性银行控股企业，总部位于宾州，提供零售及商业银行服务，涵盖储蓄账户、个人及商业贷款、财富管理等产品，服务区域覆盖宾州、俄亥俄州及西弗吉尼亚州，客户包括个人消费者和中小微企业。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
CCNE vs RIGL — 直观对比
营收规模更大
CCNE
是对方的1.2倍
$69.8M
营收增速更快
CCNE
高出24.3%
21.2%
净利率更高
RIGL
高出360.1%
24.0%
两年增速更快
RIGL
近两年复合增速
26.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $86.4M | $69.8M |
| 净利润 | $20.7M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | 48.4% | 33.2% |
| 净利率 | 24.0% | 384.0% |
| 营收同比 | 45.5% | 21.2% |
| 净利润同比 | 37.4% | 1769.2% |
| 每股收益（稀释后） | $0.69 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCNERIGL
| Q4 25 | $86.4M | $69.8M | ||
| Q3 25 | $77.7M | $69.5M | ||
| Q2 25 | $61.2M | $101.7M | ||
| Q1 25 | $56.9M | $53.3M | ||
| Q4 24 | $59.4M | $57.6M | ||
| Q3 24 | $58.5M | $55.3M | ||
| Q2 24 | $54.6M | $36.8M | ||
| Q1 24 | $54.2M | $29.5M |
净利润CCNERIGL
| Q4 25 | $20.7M | $268.1M | ||
| Q3 25 | $20.0M | $27.9M | ||
| Q2 25 | $14.0M | $59.6M | ||
| Q1 25 | $11.5M | $11.4M | ||
| Q4 24 | $15.1M | $14.3M | ||
| Q3 24 | $14.0M | $12.4M | ||
| Q2 24 | $13.0M | $-1.0M | ||
| Q1 24 | $12.6M | $-8.2M |
毛利率CCNERIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率CCNERIGL
| Q4 25 | 48.4% | 33.2% | ||
| Q3 25 | 11.7% | 40.9% | ||
| Q2 25 | 28.2% | 60.1% | ||
| Q1 25 | 25.2% | 23.9% | ||
| Q4 24 | 31.4% | 28.9% | ||
| Q3 24 | 29.6% | 25.4% | ||
| Q2 24 | 29.3% | 1.2% | ||
| Q1 24 | 28.5% | -23.6% |
净利率CCNERIGL
| Q4 25 | 24.0% | 384.0% | ||
| Q3 25 | 25.7% | 40.2% | ||
| Q2 25 | 22.8% | 58.6% | ||
| Q1 25 | 20.2% | 21.5% | ||
| Q4 24 | 25.4% | 24.9% | ||
| Q3 24 | 23.9% | 22.5% | ||
| Q2 24 | 23.7% | -2.8% | ||
| Q1 24 | 23.3% | -27.9% |
每股收益（稀释后）CCNERIGL
| Q4 25 | $0.69 | $14.11 | ||
| Q3 25 | $0.69 | $1.46 | ||
| Q2 25 | $0.61 | $3.28 | ||
| Q1 25 | $0.50 | $0.63 | ||
| Q4 24 | $0.67 | $0.82 | ||
| Q3 24 | $0.61 | $0.70 | ||
| Q2 24 | $0.56 | $-0.06 | ||
| Q1 24 | $0.55 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $527.9M | $155.0M |
| 总债务越低越好 | $84.9M | $52.5M |
| 股东权益账面价值 | $872.1M | $391.5M |
| 总资产 | $8.4B | $513.6M |
| 负债/权益比越低杠杆越低 | 0.10× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资CCNERIGL
| Q4 25 | $527.9M | $155.0M | ||
| Q3 25 | $438.1M | $137.1M | ||
| Q2 25 | $425.4M | $108.4M | ||
| Q1 25 | $520.2M | $77.1M | ||
| Q4 24 | $443.0M | $77.3M | ||
| Q3 24 | $360.9M | $61.1M | ||
| Q2 24 | $331.1M | $49.1M | ||
| Q1 24 | $301.5M | $49.5M |
总债务CCNERIGL
| Q4 25 | $84.9M | $52.5M | ||
| Q3 25 | $84.8M | $60.0M | ||
| Q2 25 | $84.7M | $60.0M | ||
| Q1 25 | $84.6M | $60.0M | ||
| Q4 24 | $84.6M | $60.0M | ||
| Q3 24 | $84.5M | $60.0M | ||
| Q2 24 | $84.4M | $60.0M | ||
| Q1 24 | $84.3M | $60.0M |
股东权益CCNERIGL
| Q4 25 | $872.1M | $391.5M | ||
| Q3 25 | $844.2M | $117.6M | ||
| Q2 25 | $637.3M | $81.9M | ||
| Q1 25 | $624.5M | $18.6M | ||
| Q4 24 | $610.7M | $3.3M | ||
| Q3 24 | $606.4M | $-14.6M | ||
| Q2 24 | $586.7M | $-29.9M | ||
| Q1 24 | $578.6M | $-31.7M |
总资产CCNERIGL
| Q4 25 | $8.4B | $513.6M | ||
| Q3 25 | $8.3B | $242.5M | ||
| Q2 25 | $6.3B | $206.7M | ||
| Q1 25 | $6.3B | $176.0M | ||
| Q4 24 | $6.2B | $164.0M | ||
| Q3 24 | $6.0B | $139.4M | ||
| Q2 24 | $5.9B | $128.4M | ||
| Q1 24 | $5.8B | $126.5M |
负债/权益比CCNERIGL
| Q4 25 | 0.10× | 0.13× | ||
| Q3 25 | 0.10× | 0.51× | ||
| Q2 25 | 0.13× | 0.73× | ||
| Q1 25 | 0.14× | 3.23× | ||
| Q4 24 | 0.14× | 18.25× | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 0.15× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $65.0M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $58.7M | — |
| 自由现金流率自由现金流/营收 | 67.9% | — |
| 资本支出强度资本支出/营收 | 7.3% | — |
| 现金转化率经营现金流/净利润 | 3.14× | 0.08× |
| 过去12个月自由现金流最近4个季度 | $91.3M | — |
8季度趋势，按日历期对齐
经营现金流CCNERIGL
| Q4 25 | $65.0M | $22.0M | ||
| Q3 25 | $7.0M | $24.0M | ||
| Q2 25 | $20.2M | $30.5M | ||
| Q1 25 | $11.6M | $-893.0K | ||
| Q4 24 | $71.5M | $14.5M | ||
| Q3 24 | $26.4M | $21.7M | ||
| Q2 24 | $10.4M | $302.0K | ||
| Q1 24 | $12.5M | $-5.0M |
自由现金流CCNERIGL
| Q4 25 | $58.7M | — | ||
| Q3 25 | $4.9M | — | ||
| Q2 25 | $17.9M | — | ||
| Q1 25 | $9.9M | — | ||
| Q4 24 | $55.2M | — | ||
| Q3 24 | $22.2M | — | ||
| Q2 24 | $4.1M | — | ||
| Q1 24 | $10.0M | — |
自由现金流率CCNERIGL
| Q4 25 | 67.9% | — | ||
| Q3 25 | 6.4% | — | ||
| Q2 25 | 29.2% | — | ||
| Q1 25 | 17.3% | — | ||
| Q4 24 | 93.0% | — | ||
| Q3 24 | 38.0% | — | ||
| Q2 24 | 7.6% | — | ||
| Q1 24 | 18.5% | — |
资本支出强度CCNERIGL
| Q4 25 | 7.3% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 3.9% | — | ||
| Q1 25 | 3.0% | — | ||
| Q4 24 | 27.4% | — | ||
| Q3 24 | 7.1% | — | ||
| Q2 24 | 11.6% | — | ||
| Q1 24 | 4.5% | — |
现金转化率CCNERIGL
| Q4 25 | 3.14× | 0.08× | ||
| Q3 25 | 0.35× | 0.86× | ||
| Q2 25 | 1.45× | 0.51× | ||
| Q1 25 | 1.01× | -0.08× | ||
| Q4 24 | 4.75× | 1.01× | ||
| Q3 24 | 1.89× | 1.75× | ||
| Q2 24 | 0.81× | — | ||
| Q1 24 | 0.99× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
